Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Poly(ADP‐Ribose) Polymerase (PARP) Inhibitors for locally advanced or metastatic breast cancer

Esta versión no es la más reciente

ver la versión actual 22 abril 2021

Información

DOI:
https://doi.org/10.1002/14651858.CD011395Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 26 noviembre 2014see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Cáncer de mama

Copyright:
  1. Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Mustafa Khasraw

    Correspondencia a: NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia

    [email protected]

    [email protected]

  • Sujata M Patil

    Epidemiology and Biostatistics, Memorial Sloan‐Kettering Cancer Center, New York, USA

  • Tiffany A Traina

    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA

  • Mark E Robson

    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, USA

Contributions of authors

  1. Draft the protocol: MK, SMP, MR

  2. Study selection: MK, TT, MR

  3. Extract data from studies: MK, TT, MR

  4. Enter data into RevMan: MK, MR

  5. Carry out the analysis: MK, SMP, MR

  6. Interpret the analysis: MK, SMP, TT, MR

  7. Draft the final review: MK, SMP, TT, MR

  8. Disagreement resolution: MK, SMP, TT, MR

  9. Update the review: MK, SMP, TT, MR

Declarations of interest

Dr Robson has served on advisory boards for Astra‐Zeneca, Pfizer, and Abbott Pharmaceuticals, all of which have PARP inhibitors under development. Dr Robson's institution also received funding from Astra‐Zeneca to conduct a clinical trial of a PARP inhibitor.

Acknowledgements

The authors would like to thank Melina Willson from the Cochrane Breast Cancer Group for her assistance and coordinating this review protocol.

Version history

Published

Title

Stage

Authors

Version

2021 Apr 22

PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer

Review

Amelia M Taylor, David Lok Hang Chan, Martin Tio, Sujata M Patil, Tiffany A Traina, Mark E Robson, Mustafa Khasraw

https://doi.org/10.1002/14651858.CD011395.pub2

2014 Nov 26

Poly(ADP‐Ribose) Polymerase (PARP) Inhibitors for locally advanced or metastatic breast cancer

Protocol

Mustafa Khasraw, Sujata M Patil, Tiffany A Traina, Mark E Robson

https://doi.org/10.1002/14651858.CD011395

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.